Majedie Asset Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
$11.1M Buy
135,087
+12,739
+10% +$1M 0.91% 33
2021
Q4
$9.39M Sell
122,348
-23,311
-16% -$1.86M 0.71% 46
2021
Q3
$10.9M Buy
145,659
+23,016
+19% +$1.75M 0.83% 36
2021
Q2
$9.54M Buy
122,643
+42,822
+54% +$3.19M 0.63% 54
2021
Q1
$5.87M Sell
79,821
-8,357
-9% -$616K 0.43% 69
2020
Q4
$6.89M Buy
88,178
+16,828
+24% +$1.29M 0.53% 51
2020
Q3
$5.65M Sell
71,350
-2,480
-3% -$194K 0.42% 48
2020
Q2
$5.45M Buy
+73,830
New +$5.56M 0.42% 46

Other funds holding MRK

Majedie Asset Management's MRK Position: Q1 2022 in Review

Majedie Asset Management increased its Merck (MRK) stake by 10% in Q1 2022, buying an estimated $1M and bringing the position to 135,087 shares worth $11.1M. The position accounts for 0.91% of the portfolio, ranked #33.

Majedie Asset Management first reported a position in MRK in Q2 2020 and has held it in 8 quarters since. 2,953 funds tracked by Wall St. Rank hold MRK as of Q1 2022.

  • Majedie Asset Management held 135,087 shares of Merck worth $11.1M as of Q1 2022.
  • Majedie Asset Management bought 12,739 Merck shares in Q1 2022, an estimated $1M.
  • Merck made up 0.91% of Majedie Asset Management's portfolio in Q1 2022, its #33 holding.
  • Majedie Asset Management first reported a position in Merck in Q2 2020 and has held it in 8 quarters since.
  • 2,953 funds tracked by Wall St. Rank held Merck as of Q1 2022.

Based on Majedie Asset Management's 13F filing for Q1 2022, filed 16 May 2022.